Last reviewed 2026-05-14 · How we verify

Dilafor AB — Portfolio Competitive Intelligence Brief

Dilafor AB pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

• Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

1. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
2. Avalo Therapeutics, Inc. · 1 shared drug class
3. Chang Gung Memorial Hospital · 1 shared drug class
4. ChemRar Research and Development Institute, LLC · 1 shared drug class
5. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
6. Cipla BioTec Pvt. Ltd. · 1 shared drug class
7. Daewon Pharmaceutical Co., Ltd. · 1 shared drug class
8. AJU Pharm Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dilafor AB:

• Dilafor AB pipeline updates — RSS
• Dilafor AB pipeline updates — Atom
• Dilafor AB pipeline updates — JSON

Cite this brief

Drug Landscape (2026). Dilafor AB — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dilafor-ab. Accessed 2026-05-14.

Related

• Dilafor AB full company profile
• All CI briefs
• Build a custom feed